喫煙を止め、再発を避けたい成人を対象としたブレニパチドの研究

基本情報

NCT ID

NCT07223840

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

222

治験依頼者名

Eli Lilly and Company

概要

This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)